The Future of PsA Save
Speaker Bios in order of appearance:
Jack Cush, MD: Dr. Cush is the Director of Clinical Rheumatology at the Baylor Research Institute and a Professor of Medicine and Rheumatology at Baylor University Medical Center in Dallas, TX. He is the Executive Editor of RheumNow.com and Co-Editor of the online textbook RheumaKnowledgy.com. Dr. Cush’s research and interests include novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, pregnancy and Still’s disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology. He can be followed on Twitter: @RheumNow. Disclosure: Investigator for – Abbvie, Astra-Zeneca, Genentech, Janssen, Novartis, Pfizer. Consultant/Advisor to Abbvie, Amgen, BMS, Celgene, Genentech, Horizon, Lilly, Novartis, UCB.
Laura Coates, MD: Laura Coates is an Associate Professor and NIHR Clinician Scientist whose research focuses on optimal therapeutic strategies in psoriatic arthritis (PsA). Her PhD focused on the development of the minimal disease activity criteria for PsA and establishment of the TICOPA trial, the first study to show the benefit of treating to target in PsA. Her research is clinical and focuses on psoriatic arthritis and the spondyloarthritides including early diagnosis of PsA, development of PsA specific and validated outcome measures, optimal treatment pathways and strategies in PsA. She is chair of the British PsA Consortium (BritPACT) and a member of GRAPPA.
Eric M Ruderman, MD: Dr. Ruderman received his undergraduate degree in English Literature from Princeton University. He attended medical school at Albert Einstein College of Medicine followed by a residency in internal medicine at the Hospital of the University of Pennsylvania. He completed his rheumatology fellowship at Brigham and Women's Hospital, with a concurrent research fellowship under a T32 training grant at the Harvard School of Public Health. At Northwestern since 2000, where he has held a number of roles, currently Associate Chief, Clinical Affairs for the Division of Rheumatology. His academic focus is on linking the clinical and research enterprises within the division to foster novel translational work that will advance the field of rheumatology. His clinical focus is on Rheumatoid Arthritis, Psoriatic Arthritis (combined program with Dermatology), Spondyloarthritis.
Dafna Gladman, MD: Dr. Gladman is Professor of Medicine at the University of Toronto, and Senior Scientist at the Krembil Research Institute and Schroeder Arthritis Institute. She is Deputy Director of the Centre for Prognosis Studies in The Rheumatic Diseases, Director, Psoriatic Arthritis Program, University Health Network and co‐Director of the University of Toronto Lupus Clinic. Dr. Gladman’s research focuses on psoriatic arthritis (PsA) and systemic lupus erythematosus with emphasis on database development, prognosis studies, genetic markers, assessment instruments, and quality of life measures. The Toronto PsA Clinic was established in 1978 and is the largest PsA longitudinal cohort in the world. Dr. Gladman’s laboratory research program involves genetic and biomarkers studies of PsA making this a truly translational research program.
Gladman authored 2 books, edited 3 books, and has over 900 peer‐reviewed publications, 141 chapters and invited publications and over 1250 published abstracts. Dr. Gladman established the International Psoriasis and Arthritis Research Team (IPART) and is Past‐President of the international Group for Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), a Co – PI of the SpondyloARthritis Research Consortium of Canada (SPARCC).
Dr. Gladman has received numerous awards in including the Verna Wright Prize for outstanding contribution to the field of Psoriatic Arthritis, the Carol Nachman Prize for outstanding research activities in the field of rheumatology and the American College of Rheumatology Clinician Investigator award. Dr. Gladman is a Master of the American College of Rheumatology and the Canadian Rheumatology Association, and she has been elected to the Canadian Academy of Science and SigmaFi.
Philip Conaghan MBBS PhD FRACP FRCP: Professor Philip Conaghan MBBS PhD FRACP FRCP is Director of the Leeds Institute of Rheumatic and Musculoskeletal Medicine (a EULAR Centre of Excellence) at the University of Leeds and Deputy Director of the NIHR Leeds Biomedical Research Centre, UK. His research is based on understanding pathogenesis and developing effective therapies for people with common arthritides, with interests in pharmaco-epidemiology, outcomes, and clinical trial design. He is an executive member of the international outcomes group OMERACT and was inaugural Chair of the EULAR Standing Committee on Musculoskeletal Imaging. He is co-editor of the Oxford Textbook of Rheumatology and has authored/co-authored over 650 publications as original research, reviews and book chapters. In 2021 he received the international Carol Nachman award for Rheumatology.
Dr Ying Ying Leung: Dr Ying Ying Leung (Katy) is a senior consultant in the Department of Rheumatology and Immunology at Singapore General Hospital (SGH) and an associate professor at Duke-NUS Medical School in Singapore. A passionate researcher, she received a National Medical Research Council Transition Award in 2013 and a Clinician Scientist Award in 2017. Her research interests include osteoarthritis, psoriatic arthritis, biomarkers and outcome measures. She serves in the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) education committee since 2018 and has been co-chair of the outcome measures working group of GRAPPA since 2017. She is also a member of the Outcome Measures in Rheumatology Technical Advisory Group (OMERACT-TAG) since 2020. She is the co-chair of scientific committee in Asia Pacific League of Associations for Rheumatology (APLAR) since 2021.
Dr. Kenneth B. Gordon: Dr. Kenneth B. Gordon is Professor and Chair of Dermatology at the Medical College of Wisconsin. He received his medical degree from Columbia University College of Physicians and Surgeons in New York and completed a residency in internal medicine at Beth Israel Hospital and Harvard University. He completed his dermatology residency and an immunology fellowship at Northwestern University Medical School in Chicago. Dr. Gordon’s clinical and research interests are in psoriasis and clinical trials, where he has published widely, and is a highly sought-after speaker on these topics. He has received research support from diverse sources and has been involved in the development of several psoriasis medications.
Dr. Alexis Ogdie: Dr Ogdie is Associate Professor of Medicine and Epidemiology, and Deputy Director of the Center for Clinical Epidemiology and Biostatistics in the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA and is Director of the Penn Psoriatic Arthritis and Spondyloarthritis Program. Dr Ogdie’s research program focuses on pharmacoepidemiology and observational studies of psoriatic arthritis (PsA). The mission of her research is to improve outcomes in PsA by accelerating diagnosis, increasing the focus on meaningful, patient-centered outcomes, and in developing and advancing methods for precision medicine. Her areas of expertise include epidemiology and pharmacoepidemiology, biostatistical methods for observational studies (e.g. time to event modeling, prediction modeling), outcome measures (e.g. qualitative and quantitative/psychometric assessment), clinical trial design and more general qualitative methods (e.g. survey, focus group and interview studies). Dr Ogdie’s recent work has focused on pragmatic trial design in PsA, which is the basis for an R01 funded by NIAMS (R01 AR072363), and trial simulation studies to inform pragmatic trial design, with statistical collaborator Alisa Stephens. Dr Ogdie is currently co-leading a trial to examine the impact of dietary interventions on PsA disease activity and conducted a pilot trial of physical activity in inflammatory arthritis. Both trials employ concepts from behavioral economics to enhance the effectiveness of the interventions. Recently, her research group has focused their efforts on early identification of PsA through a better understanding of the predictors of disease and how this can be implemented in electronic medical records. They are also working on design of a trial to test prevention of PsA through the treatment of psoriasis.
Dr. Christopher Ritchlin: Christopher Ritchlin, MD, MPH is a Professor of Medicine and former Chief of Allergy, Immunology & Rheumatology at the University of Rochester Medical Center in Rochester, New York. He joined the faculty of the University of Rochester School of Medicine and Dentistry in 1991. In 2009, he earned an MPH degree at the University. He is a member of the ACR Division Directors Special Committee and also directs the mentoring of junior investigators in the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). He has published over 160 manuscripts on topics related to psoriatic arthritis, lymphatic mechanisms of joint flare and bone remodeling.
RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty.